Novo Nordisk Aktie
41,50
EUR
+1,37
EUR
+3,40
%
41,59
EUR
+1,70
EUR
+4,26
%
Novo Nordisk jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Novo Nordisk Aktie Analyse
| 17.01.20 | Novo Nordisk overweight | Barclays Capital | |
| 17.01.20 | Novo Nordisk Neutral | UBS AG | |
| 17.01.20 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 16.01.20 | Novo Nordisk overweight | Barclays Capital | |
| 16.01.20 | Novo Nordisk Outperform | Credit Suisse Group | |
| 06.01.20 | Novo Nordisk neutral | Morgan Stanley | |
| 06.01.20 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 06.01.20 | Novo Nordisk kaufen | Bernstein Research | |
|
Werbung
|
|||
| 17.12.19 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 12.12.19 | Novo Nordisk Hold | Deutsche Bank AG | |
| 06.12.19 | Novo Nordisk Neutral | UBS AG | |
| 27.11.19 | Novo Nordisk Reduce | HSBC | |
| 21.11.19 | Novo Nordisk Hold | Deutsche Bank AG | |
| 21.11.19 | Novo Nordisk Neutral | UBS AG | |
| 21.11.19 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 21.11.19 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 18.11.19 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 18.11.19 | Novo Nordisk Neutral | UBS AG | |
| 18.11.19 | Novo Nordisk overweight | Barclays Capital | |
| 11.11.19 | Novo Nordisk Hold | Deutsche Bank AG | |
| 06.11.19 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.11.19 | Novo Nordisk Outperform | Credit Suisse Group | |
| 04.11.19 | Novo Nordisk Equal weight | Barclays Capital | |
| 04.11.19 | Novo Nordisk Hold | Deutsche Bank AG | |
| 04.11.19 | Novo Nordisk Outperform | Bernstein Research | |
| 04.11.19 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 01.11.19 | Novo Nordisk Equal weight | Barclays Capital | |
| 01.11.19 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 01.11.19 | Novo Nordisk buy | UBS AG | |
| 01.11.19 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 28.10.19 | Novo Nordisk Outperform | Credit Suisse Group | |
| 21.10.19 | Novo Nordisk buy | UBS AG | |
| 09.10.19 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.10.19 | Novo Nordisk Outperform | Credit Suisse Group | |
| 30.09.19 | Novo Nordisk Equal-Weight | Morgan Stanley | |
| 27.09.19 | Novo Nordisk Equal-Weight | Morgan Stanley | |
| 24.09.19 | Novo Nordisk Hold | Deutsche Bank AG | |
| 23.09.19 | Novo Nordisk Equal weight | Barclays Capital | |
| 23.09.19 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 23.09.19 | Novo Nordisk Hold | Deutsche Bank AG | |
| 23.09.19 | Novo Nordisk Reduce | HSBC | |
| 20.09.19 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 20.09.19 | Novo Nordisk Halten | Independent Research GmbH | |
| 20.09.19 | Novo Nordisk Underperform | Jefferies & Company Inc. | |
| 19.09.19 | Novo Nordisk Conviction Buy List | Goldman Sachs Group Inc. | |
| 18.09.19 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 13.09.19 | Novo Nordisk Neutral | Merrill Lynch & Co., Inc. | |
| 12.09.19 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
| 09.09.19 | Novo Nordisk Outperform | Bernstein Research | |
| 05.09.19 | Novo Nordisk overweight | JP Morgan Chase & Co. | |
Werbung
Werbung